IMCR - Immunocore touts updated phase 1 results for melanoma asset brenetafusp May, 31 2024 04:31 PM Immunocore Holdings plc 2024-05-31 16:31:58 ET More on Immunocore Immunocore GAAP EPS of -$0.49 misses by $0.13, revenue of $70.5M beats by $1.32M Cantor sees strong year ahead for oncology M&A Seeking Alpha’s Quant Rating on Immunocore Historical earnings data for Immunocore Financial information for Immunocore For further details see: Immunocore touts updated phase 1 results for melanoma asset brenetafusp